Trials / Unknown
UnknownNCT03688451
Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma
A Pilot Study to Access the Feasibility and Safety of Intrathecal Rituximab Added to Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20 Positive Non Hodgkin Lymphoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Tahir Latif · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to learn if giving rituximab, the study drug, right into the spinal canal along with chemotherapy drugs like methotrexate is possible and safe.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab | Intrathecal administration over 3-5 minutes |
Timeline
- Start date
- 2018-10-29
- Primary completion
- 2023-12-01
- Completion
- 2024-10-01
- First posted
- 2018-09-28
- Last updated
- 2023-03-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03688451. Inclusion in this directory is not an endorsement.